Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD4+ T-lymphocytes natural decrease in HAART-naïve HIV-infected adults in Abidjan.

J Duvignac1, X Anglaret, A Kpozehouen

  • 1INSERM U593, Bordeaux, France. Julien.Duvignac@isped.u-bordeaux2.fr

HIV Clinical Trials
|January 25, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel integrase mutations linked to genotypic DTG resistance in non-B HIV-1 strains from African participants: The DTG RESIST study.

medRxiv : the preprint server for health sciences·2025
Same author

[Primary isoniazid preventive therapy : A strategy still relevant in the era of test and treat ; literature review].

Revue d'epidemiologie et de sante publique·2022
Same author

Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic.

Infectious diseases and therapy·2022
Same author

Effects of Age, Level of Education and HIV Status on Cognitive Performance in West African Older Adults: The West Africa IeDEA Cohort Collaboration.

AIDS and behavior·2021
Same author

[Sexual Behaviours at Risk of HIV Infection among Male to Female Transgender People in Benin].

Bulletin de la Societe de pathologie exotique (1990)·2021
Same author

A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.

Journal of virology·2021
Same journal

Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.

HIV clinical trials·2019
Same journal

Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.

HIV clinical trials·2019
Same journal

Participant characteristics and clinical trial decision-making factors in AIDS malignancy consortium treatment trials for HIV-infected persons with cancer (AMC #S006).

HIV clinical trials·2019
Same journal

Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial.

HIV clinical trials·2019
Same journal

Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.

HIV clinical trials·2019
Same journal

Natural control of HIV infection in young women in South Africa: HPTN 068.

HIV clinical trials·2018
See all related articles

The natural decline of CD4 cells in HIV-infected adults in sub-Saharan Africa is similar to that in industrialized nations. Lower baseline body mass index (BMI) is linked to a faster CD4 count decrease.

Area of Science:

  • Immunology
  • Public Health
  • Epidemiology

Background:

  • Human Immunodeficiency Virus (HIV) infection leads to a decline in CD4+ T-lymphocyte counts, crucial for immune function.
  • Understanding the natural history of CD4+ T-cell decline in untreated HIV-infected individuals is vital for disease management and treatment strategies.

Purpose of the Study:

  • To investigate the rate of natural CD4+ T-cell decline in HIV-infected adults in sub-Saharan Africa.
  • To identify factors influencing this decline, particularly in the absence of severe morbidity or highly active antiretroviral therapy (HAART).

Main Methods:

  • A 7-year prospective cohort study involving biannual CD4+ T-cell measurements.
  • Joint modeling approach combining a linear mixed model for CD4+ T-cell changes and a survival model for drop-out.

Related Experiment Videos

  • Follow-up was censored at severe morbidity events or initiation of HAART.

    • Main Results:

    • The rate of CD4+ T-cell decline was primarily associated with follow-up duration and baseline body mass index (BMI).
    • Mean annual CD4+ T-cell decrease varied significantly with baseline BMI: -81/mm³ (-2.2%) for BMI 16 kg/m², -69/mm³ (-1.7%) for BMI 20.4 kg/m², and -55/mm³ (-1.2%) for BMI 25 kg/m².
    • A steeper CD4+ T-cell decline was independently linked to shorter event-free follow-up periods.

    Conclusions:

    • The natural CD4+ T-cell decrease in sub-Saharan African adults, before HAART initiation and without severe morbidity, is comparable to rates observed in industrialized countries.
    • Close monitoring of CD4+ T-cell counts is recommended for adults with low BMI in sub-Saharan African settings, where measurements may be less frequent.